FOAMIX - DAILY CHART
Foamix Pharmaceuticals its gathering the attention of investors around the reporting of worse than expected earnings with an EPS of -0.35, representing -2.94% of the forecasted. The company also announced the Merging with Menlo Therapeutics (MNLO) focused on the development and commercialization of therapeutics for dermatologic indications. These news can imply an increase in volatility on the asset and further investors' especulation.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.